8-K: Cue Biopharma Reports Strong Q4, Full Year 2025 Results

Cue Biopharma announced improved financial results for Q4 and full year 2025, driven by a new strategic collaboration and progress in its lead autoimmune asset, CUE-401.

Summary

• Reported collaboration revenue of $21.9 million for Q4 2025, a significant increase from $1.6 million in Q4 2024.
• Full year 2025 collaboration revenue reached $27.5 million, up from $9.3 million in 2024.
• Achieved net income of $1.585 million in Q4 2025, compared to a net loss of $9.496 million in Q4 2024.
• Reduced full year 2025 net loss to $26.602 million from $40.674 million in 2024.
• Advanced CUE-401, the lead asset for autoimmune and inflammatory diseases, towards IND readiness, with positive preclinical safety and tolerability data.
• Entered into a strategic collaboration and license agreement with ImmunoScape, receiving $9.5 million in upfront payments in Q4 2025 and an additional $5 million expected in November 2026.
• Received a 40% equity stake in ImmunoScape and is eligible for high-single digit royalties.
• Raised net proceeds of $10.2 million through an underwritten public offering.
• Appointed Lucinda Warren as Chief Financial and Business Officer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report. The significant increase in revenue and reduction in net loss, driven by a key collaboration, along with positive preclinical data for CUE-401, are strong indicators of progress. However, the persistent full-year loss and the 'going concern' warning temper the overall sentiment.

Positives

• Collaboration revenue significantly increased to $21.9 million in Q4 2025 and $27.5 million for the full year 2025, primarily due to the ImmunoScape agreement.
• Achieved net income of $1.585 million in Q4 2025, a substantial improvement from a net loss of $9.496 million in the prior year quarter.
• Reduced full year 2025 net loss by over $14 million compared to 2024.
• Successfully advanced CUE-401 for IND readiness, demonstrating positive preclinical safety and tolerability in non-GLP studies with no adverse events.
• Secured a strategic collaboration and license agreement with ImmunoScape, including $15 million in upfront payments ($9.5 million received, $5 million expected) and a 40% equity stake.
• Eligible for high-single digit royalties from the ImmunoScape collaboration.
• Strengthened cash position, with cash and cash equivalents increasing to $27.1 million as of December 31, 2025, from $22.5 million in 2024.
• Successfully raised $10.2 million in net proceeds through an underwritten public offering.

Negatives

• Despite significant improvements, the company reported a net loss of $26.602 million for the full year 2025.
• Research and development expenses increased to $16.5 million in Q4 2025 and $37.7 million for the full year 2025, driven by CUE-401 manufacturing and ImmunoScape collaboration costs.
• General and administrative expenses increased for the full year 2025, partly due to severance paid to the former chief executive officer and professional fees related to collaboration agreements.
• The company has a limited operating history, limited cash, and a history of losses.
• The company has a current going concern determination, indicating insufficient capital to continue operations beyond the next twelve months.

Risks

• Ability to maintain the collaboration with ImmunoScape.
• Limited operating history, limited cash, and a history of losses.
• Ability to obtain adequate financing to fund business operations in the near term and successfully remediate its current going concern determination that it does not have sufficient capital on hand to continue operations beyond the next twelve months.
• Ability to achieve profitability.
• Potential setbacks in research and development efforts, including negative or inconclusive results from preclinical studies or clinical trials, or inability to replicate positive results in later clinical trials.
• Serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials.
• Ability to secure required U.S. Food and Drug Administration (FDA) or other governmental approvals for product candidates and the breadth of any approved indication.
• Adverse effects caused by public health pandemics, including possible effects on operations and clinical trials.
• Delays and changes in regulatory requirements, policy, and guidelines, including potential delays in submitting required regulatory applications to the FDA.
• Reliance on licensors, collaborators, contract research organizations, suppliers, and other business partners.
• Ability to obtain adequate financing to fund business operations in the future and ability to continue as a going concern.
• Ability to maintain and enforce necessary patent and other intellectual property protection.
• Competitive factors.
• General economic and market conditions.

Future Outlook

The company believes it is well positioned to further advance its Immuno-STAT platform and lead autoimmune asset, CUE-401, toward the clinic to address major unmet needs in autoimmune disease treatment. It anticipates CUE-401 has the therapeutic potential to restore immune balance. The company expects to receive an additional $5 million upfront payment from ImmunoScape in November 2026 and plans to host a virtual R&D Day event highlighting CUE-401 within the next couple of weeks.

Management Comments

• "During the fourth quarter and throughout the full year 2025, the Company successfully met its strategic development goals and objectives that demonstrated significant progress towards establishing potential first-in-class and best-in-class assets for patients suffering with autoimmune diseases."
• "With these strategic deliverables and continued progress to date, we believe we are well positioned to further advance our differentiating Immuno-STAT platform and lead autoimmune asset, CUE-401, toward the clinic to address major unmet needs in autoimmune disease treatment."

Industry Context

StockSavvy.ai notes that the biopharmaceutical sector, particularly in autoimmune and oncology cell therapies, is highly competitive and capital-intensive. Cue Biopharma's strategic collaboration with ImmunoScape for solid tumors and the advancement of its lead autoimmune asset, CUE-401, position it within key growth areas. The focus on selective T-cell modulation aligns with a broader industry trend towards more targeted immunotherapies, aiming to reduce systemic side effects common with older treatments.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders**: Potential for increased value due to strategic collaborations, pipeline progress, and improved financial metrics, but ongoing 'going concern' risk remains a concern.
• **Employees**: Reduction in headcount noted as a factor in decreased employee compensation, indicating potential restructuring or efficiency measures.
• **Customers/Patients**: Advancement of CUE-401 towards IND readiness offers future therapeutic potential for autoimmune and inflammatory diseases.
• **Collaborators (ImmunoScape)**: Strengthened partnership with upfront payments and equity stake, indicating mutual commitment to developing cell therapies for solid tumors.
• **Creditors**: Improved cash position and reduced net loss may positively impact creditworthiness, though the 'going concern' warning highlights continued financial scrutiny.

Next Steps

• Announce a Virtual R&D Day event highlighting CUE-401 within the next couple of weeks.
• Continue to advance the Immuno-STAT platform and CUE-401 toward the clinic.
• Receive an additional $5 million upfront payment from ImmunoScape in November 2026.

Key Dates

Recommendation

While Cue Biopharma demonstrated significant financial improvements in Q4 and full year 2025, driven by a substantial collaboration with ImmunoScape and progress in its CUE-401 pipeline, the company still reported a full-year net loss and carries a 'going concern' warning. The positive developments are encouraging, but the underlying financial stability issues warrant a cautious 'hold' recommendation. Investors should monitor the company's ability to secure future financing and advance its pipeline to address the going concern.

Keywords

Biopharma, Autoimmune Disease, Inflammatory Disease, CUE-401, Immuno-STAT, T-cells, IND Readiness, ImmunoScape, Cell Therapy, Solid Tumors, Clinical Stage, Biologics, SEC Filing, Financial Results